RGNT 6-K
Regentis Biomaterials Ltd. (RGNT)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of July 2026
Commission File Number: 001-42834
Regentis Biomaterials Ltd.
(Translation of registrant’s name into English)
60 Medinat Hayehudim, Herzliya, Israel 4676652
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On July 2, 2026, Regentis Biomaterials Ltd. (the “Company”) convened an Annual General Meeting of Shareholders (the “Annual General Meeting”). However, the Annual General Meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Annual General Meeting will be reconvened on Tuesday, July 9, 2026 at 3:00 p.m., Israel time, at the offices of the Company’s attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Regentis Biomaterials Ltd. | |
| Date: July 2, 2026 | /s/ Ehud Geller |
|
Ehud Geller Chairman and Chief Executive Officer |
2